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In the 1970s, the identification of the histamine H2-receptor by Black and the
subsequent development of histamine H -receptor antagonists revolutionized
our understanding and treatment of acidlpeptic disorders. More recently, the
identification of hydrogen-potassium-stimulated adenosine triphosphatase
(H+/K+-ATPase) as the proton pump of the parietal cell and the recognition of
the prominent role ofHelicobacterpylori in the pathogenesis of duodenal and
gastric ulceration have heralded a new revolution in ourunderstanding and treat-
ment of these disorders. Substituted benzimidazole compounds (omeprazole,
lansoprazole and pantoprazole) that covalently bind to and inactivate the proton
pump allow complete and prolonged inhibition of acid secretion. Not only can
peptic ulcers now be healed more rapidly with proton pump inhibitors, but
refractory ulcers have all but disappeared. Eradication of H. pylori with antibi-
otics offers, for the first time, a permanent cure for most duodenal and many
gastric ulcers.
PROTON PUMP INHIBITORS
The pathogenesis of acid/peptic disorders (duodenal ulcer, gastric ulcer and reflux
esophagitis) involves an imbalance between aggressive (e.g., acid, pepsin, Helicobacter
pylori and nonsteroidal anti-inflammatory drugs) and defensive (e.g., epithelial cell
integrity, mucus, bicarbonate and mucosal blood flow) factors. Although an important role
has been established for H. pylori in the development of duodenal and gastric ulcer, it
should be emphasized that gastric acid still remains central to the pathogenesis of these
disorders and Schwartz's dictum, "no acid - no ulcer," remains valid. These disorders can
be completely healed and remission maintained with antisecretory therapy [1].
Furthermore, in patients with duodenal ulcer disease, peak acid secretion remains elevat-
ed even after eradication of H. pylori [2].
With the recent introduction ofPPIsb into clinical practice, acid inhibitory therapy for
peptic ulcer disease has come a full circle. That is, we went from intensive four times per
day dosing ofH2 antagonists in the 1970s to twicedaily, and eventually a single daily dose
in the 1980s, with equivalent healing rates. The use ofPPIs has ushered areturn to aggres-
sive acid inhibitory therapy. PPIs are being touted as first-line therapy for acid/peptic dis-
orders and are being used in higher and higher doses. Such an approach is warranted in
severe gastroesophageal reflux disease, in which it has been shown that acute healing at
eight weeks correlates with the duration in hours that the intragastric pH is maintained
above 4.0 [3]. PPIs suppress daytime, nighttime and especially meal-stimulated acid
secretion more effectively than H2 antagonists and, thus, yield higher healing rates forero-
sive and ulcerative esophagitis. After eight to 12 weeks, 74 to 96 percent of omeprazole-
treated patients with esophagitis are healed compared with 28 to 66 percent of patients
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treated with H2 antagonists [4]. Once healed, omeprazole, 20 mg/day, is more effective in
preventing relapses, with 77 to 89 percent remaining in remission at twelve months com-
pared with 25 to 46 percent of those taking 150 mg ranitidine twice daily [5, 6].
Healing rates for duodenal and gastric ulcer correlate with the degree and duration of
24-hr acid suppression as well as the length of treatment. For duodenal ulcer, suppression
of24-hr and nocturnal acid secretion appears to be most important. Conventional doses of
H2 antagonists maintain intragastric pH at or above 3 for about 10 hours, which is six to
seven hours less than that which can be achieved with single daily doses of20 mg omepra-
zole or 15 mg lansoprazole. Accordingly, duodenal ulcers heal more rapidly on standard
doses of PPIs than on H2 antagonists, with complete healing at four and eight weeks,
respectively. Thus, depending upon price, it may be more cost-effective to treat duodenal
ulcers for four weeks with a PPI instead of eight weeks with an H2 antagonist [7, 8]. In
contrast to duodenal ulcer, the most important parameter for healing of gastric ulcer
appears to be length of treatment, with 85 to 95 percent of both omeprazole- and raniti-
dine-treated ulcers healed at eight weeks [7, 9, 10]. Thus, for gastric ulcer, eight-week
therapy with an H2 antagonist may be more cost-effective.
HELICOBACTER PYLORI
H. pylori is associated with chronic type B gastritis, duodenal and gastric ulcer, and
gastric adenocarcinoma and lymphoma. Eradication ofH. pyloni with antimicrobial agents
prevents relapse ofduodenal and gastric ulcer and causes regression ofprimary, low-grade
B cell lymphoma of the stomach. It remains to be determined whether eradication is indi-
cated in patients with non-ulcer dyspepsia, hyperplastic gastric polyps or a family history
of adenocarcinoma of the stomach.
The "gold standard" regimen for eradication of H. pylori consists of bismuth and
metronidazole plus either amoxicillin or tetracycline for two weeks. Another triple thera-
py regimen, consisting of metronidazole, clarithromycin and omeprazole, each given
twice daily, shows promise with preliminary studies also showing a 90 percent eradication
rate. Problems with triple therapy include: 1) resistance to metronidazole (25 percent in
the U.S.; higher elsewhere), 2) high side-effect profile (25 to 35 percent) including antibi-
otic-associated diarrhea and colitis, 3) poor compliance due to the large number of tablets
to be ingested daily (up to 16 tablets/day) and 4) induction of antibiotic resistance, not
only in H. pylori but in other colonizers such as Streptococcus, Staphylococcus, H.
influenza, and Enterococcus. None of the present regimens are ideal. Dual therapies, e.g.,
omeprazole plus amoxicillin, previously extolled as the treatment of choice for eradica-
tion of H. pylori, have now fallen into disrepute with unacceptably low eradication rates
of 45 to 80 percent [11]. The search for a simple, inexpensive, well-tolerated, selective,
yet effective regimen continues.
Successful eradication is generally accepted as inability to detect the organism in gas-
tric biopsy material (rapid urease test, histology or culture) four weeks after completion
of antibiotic therapy. When patients have been re-evaluated at twelve months, recurrence
has been noted in11 to 19 percent [12, 13]. DNA fingerprinting techniques indicate that
recurrence of H. pylori after apparently successful treatment is mainly attributable to
recrudescence ofpersistent infection rather than reinfection. During a four-week treatment
of duodenal ulcer patients with omeprazole, there is a significant reduction in the number
of patients with H. pylori in the antrum and a significant increase in those with H. pylori
only in the fundus [14]. Thus, a greater number ofpersistent infections at four weeks may
be detected iffundic, in addition to antral, biopsies are obtained. It is possible that our pre-
sent definition oferadication may need to be revised and more sensitive techniques devel-
oped to assess residual infection.
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MANAGEMENT STRATEGIES
The National Institutes of Health Consensus Development Conference on H. pylori
recommended that patients with documented duodenal or gastric ulcer and infection with
H. pylon be treated with antimicrobial agents in an attempt to eradicate the organism,
whether on first presentation with the illness or on recurrence [15]. A more recent cost-
comparison, using decision analysis, supports the notion that initial therapy with antibi-
otics plus an antisecretory agent provides the lowest costs per symptomatic cure [16].
Confirmation ofH. pylori eradication is probably not necessary in patients with noncom-
plicated peptic ulcer disease but is mandatory in patients with previous ulcer complica-
tions.
A provocative cost-effectiveness analysis challenges the NIH recommendation that
both the presence of an ulcer and H. pylori infection be documented before antibiotic
medications intended to eradicate the organism be prescribed [17]. Although endoscopy
precisely guided diagnosis and treatment and, thus, reduced the number of patients
exposed to unnecessary antibiotics, it was almost twice as costly as empiric antisecretory
and antibiotic therapy per patient treated ($1584 vs. $818) or per ulcer cured ($8045 vs.
$4155). In a prospective trial in Denmark, comparing empiric H2 antagonists to immedi-
ate endoscopy [18], 65 percent ofempirically-treated patients with dyspepsia eventually
required endoscopy. At this rate ofrecurrent symptoms, the cost-effectiveness advantage
ofempiric antibiotic therapy will be minimal. In this environment ofcompetitive managed
care, the onus is squarely on us, as gastroenterologists, to bring down the cost ofesopha-
gogastroduodenoscopy. At less than $500, initial endoscopy becomes the most economi-
cal strategy.
Although it is an important consideration, cost-effectiveness should not be the over-
riding factorinfluencing our decision processes. It should be noted that only aminority of
patients, less than 10 percent, presenting to their primary-care physicians with upper
abdominal complaints have an ulcer; most have gastroesophageal reflux disease or non-
ulcer dyspepsia, conditions that do not respond to antimicrobial therapy. Even in patients
with documented peptic ulcer disease, not all ulcers are due to H. pylon - a large pro-
portion are non-steroidal anti-inflammatory drug (NSAID)-induced. It is notreasonable to
expose such a large number ofpatients unnecessarily to the risks oftriple antibiotic ther-
apy and to burden society with increasing numbers of antibiotic resistant organisms.
Multidrug resistant mutations of Streptococcus, Staphylococcus and Enterococcus are
already inflicting increasing morbidity and mortality on our patients.
THEORETICAL CONCERNS: HYPERGASTRINEMIA
Gastrin is the major hormonal stimulant of gastric acid secretion and is a mucosal
growth factor. In the antrum, the secretion of gastrin is regulated via a feedback mecha-
nism, whereby an increase in luminal acidity stimulates somatostatin secretion, which, in
turn, attenuates gastrin secretion. Accordingly, a decrease in luminal acidity, such as that
induced by PPIs, decreases somatostatin and, thus, increases gastrin secretion. In general,
the level ofhypergastrinemia is proportional to the duration and degree of acid suppres-
sion. Infection with H. pylori also increases gastrin secretion, both basal and meal-stimu-
lated, possibly by decreasing antral somatostatin release [19, 20]. Although the current
evidence suggests that the hypochlorhydria and hypergastrinemia observed during PPI
therapy have little or no clinical significance, at least up to 10 years follow-up, it should
be noted that the risk of cancer in patients with gastric resection or pernicious anemia
increases only after alatency ofdecades. Furthermore, ithas been shown thatendogenous
hypergastrinemia, induced by fundectomy, increases the spread ofhuman colon carcino-
ma transplanted into the colon ofathymic rats [21]. Although most patients on PPIs have
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only moderate increases in fasting serum gastrin levels, in about 25 percent of patients,
gastrin levels increase to over 500 pg/ml [22]. For patients maintained on long-term PPIs,
it seems prudent to check a fasting serum gastrin level at six months to one year. Ifmarked
hypergastrinemia (greater than 400 to 500 pg/ml) is found, it would seem reasonable to
reduce the dose ofthe drug and perhaps check forthe presence ofH. pylori, a gastric emp-
tying disorder or Zollinger-Ellison Syndrome.
Adenocarcinoma of the proximal stomach has the most rapidly rising incidence of
any cancer in the United States. The increase began around 1980, and the slope appears to
mirror the use of potent antisecretory drugs. Prolonged acid suppression, besides induc-
ing hypergastrinemia, may predispose to gastric malignancy by inducing intragastric bac-
terial overgrowth leading to increased gastric nitrite and N-nitroso levels and by spread-
ing H. pylori infection from the antrum to the body and fundus ofthe stomach with a has-
tening of the development of the precancerous conditions of atrophy and intestinal meta-
plasia [23]. Perhaps patients requiring long-term acid-suppressive therapy, such as those
with severe esophagitis, should be tested for H. pylori and, ifpositive, have the organism
eradicated.
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